CTI BioPharma Corp. (CTIC)
| Market Cap | 223.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.53M |
| Shares Out | 76.37M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $2.40 |
| Previous Close | $2.40 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.46 |
| Day's Range | 2.38 - 2.48 |
| Day's Volume | 347,073 |
| 52-Week Range | 0.96 - 4.13 |
SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity in...
Reddit penny stocks are full of risk and reward, which is why $100 won't hurt you, but it can reward you handsomely. The post 7 Reddit Penny Stocks to Buy if You Have $100 to Spare appeared first on Inv...
SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET....
SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2021. "The U.S. Food and Drug Administration's (FDA) a...
CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer
The FDA has accepted for review CTI BioPharma Corp's (NASDAQ: CTIC) marketing application seeking approval for pacritinib in myelofibrosis patients with severe thrombocytopenia (low platelet count). Und...
SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a ...
SEATTLE, May 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to six new employees as equity in...
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...
SEATTLE, May 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity in...
SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021,...
SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:...
CTI BioPharma's (NASDAQ:CTIC) stock has been falling Thursday, down 13.06% to a price of $2.55. Thursday the stock has been traded at a volume of 2.13 million, about 326.0% of its recent 30-day volume a...
SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...
SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies ...
CTI BioPharma Corp (NASDAQ: CTIC) has completed a rolling marketing application submission to the FDA seeking approval of pacritinib for myelofibrosis patients with severe thrombocytopenia (platelet cou...
SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S. Food and Drug Administratio...
CTI BioPharma Corp (NASDAQ: CTIC) has announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study evaluating pacritinib...
SEATTLE, March 22, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published result...
SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020. "This past quarter, CTI has ...
SEATTLE, March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wedn...
SEATTLE, Jan. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a gran...
Innovation paid off big for investors.
SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The c...
CTIC recently received FDA's accelerated approval go-ahead for pacritinib in MF patients with severe thrombocytopenia. This considerably reduces the risks associated with the company.
SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute graft ver...
SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining t...
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2020 Results - Earnings Call Transcript
SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) ...
SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10,...
CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher. The post CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104% Today ap...
CTI BioPharma: A Nano Cap With Interesting Prospects
SEATTLE, June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized ...
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at ...
CTI Biopharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma
About CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was former... [Read more...]
| Industry Biotechnology | IPO Date Mar 21, 1997 |
| CEO Adam Craig | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol CTIC |
Analyst Forecasts
According to 4 analysts, the average rating for CTI BioPharma stock is "Buy." The 12-month stock price forecast is 7.34, which is an increase of 205.83% from the latest price.